Daewoong gets stem cell facility license in Indonesia

South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational License from the Indonesian Ministry of Health.

The stem cell processing facility license permits facilities to research and produce stem cells.

The Indonesian Ministry of Health and the National Agency for Drug and Food Control of Indonesia verify the hygiene, safety, and quality management practices of the entire process through on-site inspections before granting final approval.

With this facility license, Daewoong Pharmaceutical is now able to handle stem cells locally.

Through Daewoong Biologics Indonesia, the company plans to establish a cooperative system with local clinics and hospitals and pursue research for the treatment of treatment-resistant diseases.

Starting with the production and processing of stem cells for use in clinics and hospitals, Daewoong Pharmaceutical intends to enter the regenerative treatment, cell therapy, and bio-material aesthetic markets.

Daewoong Biologics Indonesia, established in 2021 in the Jababeka Industrial Area in Cikarang, owns a cell therapy production plant, a cosmetics production plant, and a laboratory.

It also leverages advanced development technologies in all stages of stem cell clinical trials, research, and production from Daewoong Pharmaceutical's Yongin Cell Therapy Center.

Write to Ji-Hyun Lee at bluesky@hankyung.com